TY - JOUR
T1 - High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
AU - Schlenk, Richard F.
AU - Germing, U.
AU - Hartmann, F.
AU - Glasmacher, A.
AU - Fischer, I. T.
AU - del Valle y Fuentes, F.
AU - Götze, K.
AU - Pralle, H.
AU - Nerl, C.
AU - Salwender, H.
AU - Grimminger, W.
AU - Petzer, A.
AU - Hensel, M.
AU - Benner, A.
AU - Zick, L.
AU - Döhner, K.
AU - Fröhling, S.
AU - Döhner, H.
N1 - Funding Information:
We thank the members of the AML Study Group for providing leukemia specimens and clinical data. This work was supported by Grant 01GI9981 from the Bundesministerium für Bildung und Forschung (Kompetenznetz ‘Akute und chronische Leukämien’), Germany.
PY - 2005/6
Y1 - 2005/6
N2 - The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m2 q12h, days 1-3; mitoxantrone 10 mg/m2, days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 × 109/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.
AB - The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m2 q12h, days 1-3; mitoxantrone 10 mg/m2, days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 × 109/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.
KW - Activating FLT3 mutations
KW - Acute promyelocytic leukemia
KW - Additional chromosomal aberrations
KW - High-dose cytarabine
UR - http://www.scopus.com/inward/record.url?scp=20844433082&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2403766
DO - 10.1038/sj.leu.2403766
M3 - Article
C2 - 15843821
AN - SCOPUS:20844433082
SN - 0887-6924
VL - 19
SP - 978
EP - 983
JO - Leukemia
JF - Leukemia
IS - 6
ER -